Browse studies
Find your next paid study
3 recruiting studies matching your filters
Prospective Clinical Assessment Study in Children With Hypochondroplasia: ACCEL
This is a long-term, multicenter, non-interventional study of children ages 2.5 to \<17 years with hypochondroplasia (HCH).
Hypochondroplasia
Estimated
~$10 – $1,050
QED Therapeutics, a BridgeBio companyNCT06410976
A Multicenter Multinational Observational Study of Children With Hypochondroplasia
This study will assess growth over time and the clinical course of HCH in children by collecting growth measurements and other variables of interest.
Hypochondroplasia
Estimated
~$10 – $1,050
BioMarin PharmaceuticalNCT06212947
Phase 2
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Vosoritide in Infants and Young Children With Hypochondroplasia, Aged 0 to < 36 Months
The purpose of this study is to evaluate the safety and efficacy of daily administration of vosoritide in participants with HCH aged 0 to \< 36 months over a 5…
Hypochondroplasia
Estimated
~$10 – $8,750
BioMarin PharmaceuticalNCT07126262